Growing Telix gains UK approval for Illuccix

Australian radiopharma company Telix Pharmaceuticals (ASX: TLX) has gained approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its prostate cancer imaging agent, Illuccix (gallium-68 gozetotide).

The decision allows Telix to expand its European footprint as demand for PSMA-PET imaging continues to rise. The approach offers a more precise alternative to conventional imaging methods such as bone and CT scans and is becoming the standard of care for staging and recurrence detection.

A key advantage of Illuccix is that the radioisotope can be produced locally, enabling flexibility in production and scheduling and enabling broader access.